Format

Send to

Choose Destination
Hum Vaccin Immunother. 2018 Feb 1;14(2):495-499. doi: 10.1080/21645515.2017.1403705. Epub 2017 Dec 21.

Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?

Author information

1
a Institute of Child Health and Human Development, University of the Philippines Manila-National Institutes of Health , Manila , Philippines.
2
b Division of Epidemiology , ICMR-National Institute of Cholera and Enteric Diseases, Beliaghata , Kolkata , West Bengal , India.
3
c Key Laboratory of Medical Molecular Virology of MoE & MoH, and Institutes of Biomedical Sciences , Fudan University , Shanghai , China.
4
d National Institute of Hygiene and Epidemiology , Hanoi , Vietnam.
5
e Center for Vaccine Development, University School of Medicine , Baltimore , MD , USA.
6
f Department of Research, Epicentre , Paris , France.

Abstract

There are two internationally available WHO-prequalified oral rotavirus vaccines (Rotarix and RotaTeq), two rotavirus vaccines licensed in India (Rotavac and Rotasiil), one in China (Lanzhou lamb rotavirus vaccine) and one in Vietnam (Rotavin-M1), and several candidates in development. Rotavirus vaccination has been rolled out in Latin American countries and is beginning to be deployed in sub-Saharan African countries but middle- and low-income Asian countries have lagged behind in rotavirus vaccine introduction. We provide a mini-review of the leading newer-generation rotavirus vaccines and compare them with Rotarix and RotaTeq. We discuss how the development and future availability of newer-generation rotavirus vaccines that address the programmatic needs of poorer countries may help scale-up rotavirus vaccination where it is needed.

KEYWORDS:

Rotavirus; rotavirus vaccination; rotavirus vaccine

PMID:
29135339
PMCID:
PMC5806648
DOI:
10.1080/21645515.2017.1403705
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center